ArticleJournal of cachexia, sarcopenia and muscle2018
Increased Serpina3n release into circulation during glucocorticoid-mediated muscle atrophy.
Article in Journal of cachexia, sarcopenia and muscle, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 72 citations in OpenAlex.
- A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunction.Molecular cancer · 2026Article
- Skeletal muscle methylome-transcriptome disruptions during the onset and progression of colorectal cancer-induced cachexia.American journal of physiology. Cell physiology · 2026Article
- Umbilical cord mesenchymal stromal cells in sarcopenia: benefits and strategies for enhancing efficacy.Stem cell research & therapy · 2025Review
- SerpinA3N in leptin-sensitive neurons is required for energy and glucose homeostasis and autonomic regulation.Metabolism: clinical and experimental · 2025Article
- Biglycan Alleviates Age-Related Muscle Atrophy and Hepatocellular Senescence.International journal of molecular sciences · 2025Article
- hUC-MSCs and derived exosomes attenuate DEX-induced muscle atrophy through modulation of estrogen signaling pathway.Stem cell research & therapy · 2025Article
- The Effects of Vitamin D on Muscle Strength Are Influenced by Testosterone Levels.Journal of cachexia, sarcopenia and muscle · 2025Article
- Current Challenges and Future Directions in the Assessment of Glucocorticoid Status.Endocrine reviews · 2024Review
- Oncostatin M signaling drives cancer-associated skeletal muscle wasting.Cell reports. Medicine · 2024Article
- Steroid inhibited Serpina3n expression which was positively correlated with the degrees of spinal cord injury.Heliyon · 2024Article
- A new bio imagery user-friendly tool for automatic morphometry measurement on muscle cell cultures and histological sections.Scientific reports · 2024Article
- Novel Time-dependent Multi-omics Integration in Sepsis-associated Liver Dysfunction.Genomics, proteomics & bioinformatics · 2023Article
- The transcriptional regulator KLF15 is necessary for myoblast differentiation and muscle regeneration by activating FKBP5.The Journal of biological chemistry · 2023Article
- Mesenchymal stem cells alleviate dexamethasone-induced muscle atrophy in mice and the involvement of ERK1/2 signalling pathway.Stem cell research & therapy · 2023Article
- Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities.Journal of the National Cancer Institute. Monographs · 2023Article
- Article
- Is dexamethasone-induced muscle atrophy an alternative model for naturally aged sarcopenia model?Journal of orthopaedic translation · 2023Article
- SerpinA3N deficiency attenuates steatosis and enhances insulin signaling in male mice.The Journal of endocrinology · 2023Article
- Proteomic Insights into Cardiac Fibrosis: From Pathophysiological Mechanisms to Therapeutic Opportunities.Molecules (Basel, Switzerland) · 2022Review
- Potential Satellite Cell-Linked Biomarkers in Aging Skeletal Muscle Tissue: Proteomics and Proteogenomics to Monitor Sarcopenia.Proteomes · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucocorticoids (GC) play a major role in muscle atrophy. As skeletal muscle is a secretory organ, characterization of the muscle secretome elicited by muscle atrophy should allow to better understand the cellular mechanisms and to identify circulating biomarkers of this condition. Our project aimed to identify the changes in the muscle secretome associated with GC-induced muscle atrophy and susceptible to translate into circulation.
methodsWe have identified the GC-induced changes in the secretome of C
resultsThis approach led us to identify Serpina3n as one of the most markedly secreted protein in response to GC. Our original in vitro results were confirmed in vivo by an increased expression of Serpina3n in skeletal muscle (3.9-fold; P < 0.01) and in the serum (two-fold; P < 0.01) of mice treated with GC. We also observed increased levels of the human orthologue Serpina3 in the serum of Cushing's syndrome patients compared with healthy controls matched for age and sex (n = 9/group, 2.5-fold; P < 0.01). An increase of Serpina3n was also demonstrated in muscle atrophy models mediated by GC such as cancer cachexia (four-fold; P < 0.01), sepsis (12.5-fold; P < 0.001), or diabetes (two-fold; P < 0.01). In contrast, levels of Serpina3n both in skeletal muscle and in the circulation were reduced in several models of muscle hypertrophy induced by myostatin inhibition (P < 0.01). Furthermore, a cluster of data suggests that the regulation of muscle Serpina3n involves mTOR, an essential determinant of the muscle cell size.
conclusionsTaken together, these data suggest that Serpina3n may represent a circulating biomarker of muscle atrophy associated to GC and, broadly, a reflection of dynamic changes in muscle mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.